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ABSTRACT
Introduction: The aim of this study was to
develop an empirical approach to classifying
patients with transthyretin amyloidosis (ATTR)
based on clinical signs and symptoms.
Methods: Data from 971 symptomatic subjects
enrolled in the Transthyretin Amyloidosis
Outcomes Survey were analyzed using a latent
class analysis approach. Differences in health
status measures for the latent classes were
examined.
Results: A four-class latent class solution was
the best fit for the data. The latent classes were
characterized by the predominant symptoms
as severe neuropathy/severe autonomic,
moderate to severe neuropathy/low to
moderate autonomic involvement, severe
cardiac, and moderate to severe neuropathy.
Incorporating disease duration improved the
model fit. It was found that measures of health
status varied by latent class in interpretable
patterns.
Conclusion: This latent class analysis approach
offered promise in categorizing patients with
ATTR across the spectrum of disease. The four-
class latent class solution included disease
duration and enabled better detection of
heterogeneity within and across genotypes
than previous approaches, which have tended
to classify patients a priori into neuropathic,
cardiac, and mixed groups. Although this study
utilized a cross-sectional approach to disease
duration, future work could include the
application of longitudinal latent class
analyses.
Funding: Pfizer Inc., New York, NY, USA.
Electronic supplementary material The online
version of this article (doi:10.1007/s40120-015-0028-y)
contains supplementary material, which is available to
authorized users.
On behalf of the THAOS Investigators.
Trial registration: ClinicalTrials.gov number,
NCT00628745.
J. Alvir (&)
Statistical Center for Outcomes, Real-World and
Aggregate Data, Global Medicines Development,
Global Innovative Pharma Business, Pfizer, Inc.,
New York, NY, USA
e-mail: Jose.Alvir@pfizer.com
M. Stewart
Pfizer, Inc., New York, NY, USA
I. Conceic¸a˜o
Department of Neurosciences, Centro Hospitalar
Lisboa Norte, Hospital de Santa Maria, Lisbon,
Portugal
Neurol Ther (2015) 4:11–24
DOI 10.1007/s40120-015-0028-y
Keywords: Amyloidosis; Cardiomyopathy
Latent class analysis; Polyneuropathy
Transthyretin
INTRODUCTION
Transthyretin amyloidosis (ATTR) is a
progressive, degenerative disease. In familial
ATTR, a single gene mutation leads to
instability and dissociation of the TTR
tetramer, leading to amyloid formation. Wild-
type TTR can de-stabilize with advancing age
and also lead to amyloid formation.
Two common sites of amyloid deposition are
peripheral nerves and the heart. Typical early
neuropathic symptoms are paresthesias, sensory
deficit, and distal neuropathic pain with a
distal–proximal progression. Deposition in the
myocardium leads to diastolic dysfunction,
restrictive cardiomyopathy, arrhythmias, and
heart failure. Autonomic neuropathy including
erectile dysfunction, bladder paresis, postural
hypotension, and gastrointestinal symptoms
such as nausea, constipation, and diarrhea
may also occur [1, 2].
The primarily neuropathic and cardiac
phenotypes are known as transthyretin
familial amyloid polyneuropathy (TTR-FAP)
and transthyretin cardiomyopathy (TTR-CM),
respectively. However, cardiac involvement is
not uncommon in TTR-FAP, especially in later
stages, and neuropathy can appear in patients
with TTR-CM [3, 4]. Both groups can experience
autonomic symptoms.
Attempts to classify patients based on
genotype have limitations. There is significant
overlap in presenting symptoms and various
mutations have been classified on a ‘‘spectrum’’
ranging from predominantly neurologic to
predominantly cardiac, with mixed
presentations involving varying degrees of both
neurologic and cardiac symptoms in between
[4]. Even within the most common TTR
mutation, V30M (valine is replaced by
methionine at position 30), there is a
tremendous heterogeneity of presentation
[5, 6]. Classification by genotype has largely
been focused on the distinction between the
most common variant, V30M, and other
mutations that are often lumped together into
one non-V30M group, and the wild-type group.
Another a priori approach to classification of
patients with ATTR that has been widely used
classifies them into neuropathic, cardiac, and
mixed (with features of both neuropathy and
cardiomyopathy) groups based on their
phenotypic presentation, regardless of their
genotype.
Until now, little empirical research has been
undertaken to develop a classification scheme
for the full spectrum of patients with ATTR. In
this study, we grouped patients with
symptomatic ATTR based on their clinical signs
and symptoms using latent class analysis (LCA)
[7, 8] and explored the relationships between




Registrations, and Patient Consents
The Transthyretin Amyloidosis Outcomes
Survey (THAOS; ClinicalTrials.gov number,
NCT00628745) is a longitudinal, observational
registry of symptomatic patients with ATTR
(familial and wild type) and asymptomatic
mutation carriers. One of its principal aims is
to better understand and characterize the
natural history of the disease by studying a
large and heterogeneous patient population.
The design and methodology of THAOS,
including data collection and assessments, are
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described elsewhere [9]. Approval from local
Ethical Review Board/Institutional Review
Board was obtained, all participants provided
written informed consent, and use of THAOS
data for this study was approved by the THAOS
Scientific Board.
Patients
This analysis included symptomatic patients
participating in THAOS as of June 2013.
Patients who had liver or heart transplantation
prior to enrollment were excluded.
Clinical Signs and Symptom Data
Signs and symptom data collected at THAOS
enrollment were used. Individual signs and
symptoms were dichotomously coded as
‘‘present’’ if assessed as possibly or definitely
related to ATTR or ‘‘absent’’ if absent or deemed
not related to ATTR. In total, 27 signs and
symptoms reported for at least 5% of the
patients were included in this study.
Other Measures
Demographic and clinical variables were
examined. Of particular importance was ATTR
disease duration, defined as the time since
occurrence of the first ATTR symptom.
Patients were categorized by disease duration
\4 and C4 years, a cutoff value close to the
median, therefore resulting in similar numbers
of patients in each category.
Physical examination measures included
change in supine-to-standing blood pressure
(BP) and the presence of orthostatic
hypotension (systolic BP decline[20 mmHg or
diastolic BP decline[10 mmHg). The modified
body mass index (mBMI), a marker of
nutritional status (especially in patients with
autonomic dysfunction) that adjusts for serum
albumin concentration, was calculated by
multiplying BMI (kg/m2) by serum albumin
concentration (g/L). The frequency of erectile
dysfunction and depression was also examined.
The Karnofsky Performance Status is a
clinician-rated assessment of functional
impairment with scores ranging from 0 (dead)
to 100 (normal functioning/no disease). The
Karnofsky scores at enrollment were analyzed
and patients were categorized as unable to care
for self (scored 0–40), unable to work but able to
self-care (scored 50–70), and able to accomplish
normal activities and work (scored 80–100).
Patients completed the European Quality of
Life-5 dimension-3 level (EQ-5D-3L)
instrument, a standardized measure of health
consisting of five items to rate Mobility, Self-
care, Ability to perform usual activities, Pain/
discomfort, and Anxiety/depression on a 0 (not
a problem) to 2 (unable to do/extreme problem)
scale. Patients’ responses were analyzed by item
and used to calculate the EQ-5D-3L Index score.
Patients’ rating of their current health (using
the sixth item, Health State, with 0 as the worst
and 100 the best imaginable health state) was
also analyzed.
Statistical Analysis
Latent class analysis [7, 8] is a statistical method
used to find LCs (subgroups or natural taxa)
using categorical data. Generally applied in
social and behavioral science research, it is an
extension of work pioneered in psychology that
posits unobservable (latent) structures underlie
observable or manifest psychological
phenomena [10–12]. LCA classifies individuals
into mutually exclusive LCs and assumes that
all variables are independent within each LC;
thus, the LC explains the associations among
the observed variables (e.g., symptoms). Two
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sets of parameters are estimated by LCA: class
membership probabilities and item response
probabilities within each LC. Each individual
has a set of posterior probabilities, equal to the
number of LCs in the model. Individuals are
assigned to LC with the highest posterior
probability.
As recommended, we fit an initial set of
models, specifying two to six LCs, without any
grouping variable or covariates [13]. The adjusted
Bayesian information criteria (BIC) for the
separate models were then compared (smaller is
better). Measurement invariance across ATTR
disease duration groups (\4 and C4 years) was
tested by comparing a model in which there were
free estimations of the model parameters with
the same model including restrictions equating
the class membership and item response
probability parameters across groups.
Due to the large number of parameters
estimated, each model selected the optimal set
of 40 starting values to find the best parameter
estimates and avoid suboptimal local maxima
of the likelihood function [14].
The software used was the LCA procedure,
developed for SAS by the Methodology Center,
Pennsylvania State University [13, 14].
General linear models (continuous data) and
logistic regression (categorical data) were used
to test the effect of LC, ATTR duration, and the
interaction of the two on health status
measures. A log-linear model was used to
compare results for the non-ordinal groups
based on a priori classification.
RESULTS
Patients
Of the 979 individuals who were symptomatic
at enrollment, 971 had data on ATTR symptom
duration and were included in this analysis. The
mean age ± standard deviation (SD) was
53.5 ± 18.0 years. Males comprised 60% of the
sample. The median ATTR duration was
3.33 years, with mean ± SD of 5.6 ± 6.7 years,
and 57% had ATTR duration\4 years. Time
since diagnosis was available for 608 patients
with a mean ± SD of 1.8 ± 2.8 years.
Latent Class Analyses
Fit statistics were examined for two to six LC
solutions by plotting the adjusted BIC as
recommended by Nylund et al. [15]. The BIC
improved (declined) from two to five class
solutions. The four-class solution was chosen
for better stability among the potential models.
Analyses assessing the impact of ATTR duration
as a grouping variable on the LCA indicated that
it had a significant contribution (v2 = 338.7;
df = 108; P\0.0001).
Each patient had a probability calculated for
membership in each of the four LCs and was
assigned to the LC with the highest probability.
The individual posterior probabilities used to
categorize patients into LCs were strong, with
means within LC ranging from 0.91 to 0.98
(Table 1). The estimated item response
probabilities for each LC grouped by ATTR
duration are shown in Fig. 1 and in Table S1
in the electronic supplementary material (ESM).
LC1: Severe Neuropathy/Severe
Autonomic
LC1 had high probabilities of neuropathic
symptoms such as pain and tingling,
autonomic symptoms (both upper and lower
gastrointestinal, urinary, heart involvement,
and weight loss), with markedly higher
probabilities among patients with ATTR
duration of C4 years (Fig. 1a). The probability
of walking disability was high in both disease
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duration groups. This class was best described as
severe neuropathy/severe autonomic. The
symptom pattern was the same in both disease
duration groups, but with higher frequency in
those with longer disease duration (Fig. 1a). The
estimated class probabilities were 16% and 14%
among those with ATTR duration of \4 and
C4 years, respectively (Table 1).
LC2: Moderate to Severe Neuropathy/Low
to Moderate Autonomic Involvement
LC2 exhibited moderate to severe neuropathic
symptoms, but no clear pattern of increase with
longer ATTR duration (Fig. 1b). Numbness,
temperature, tingling, muscle weakness, and
walking disability were more probable with
longer ATTR duration; vomiting, nausea, early
satiety, and dizziness were more prevalent
among those with shorter ATTR duration. This
class included 17% and 27% of the patients
with ATTR duration of \4 and C4 years,
respectively (Table 1).
LC3: Severe Cardiac
LC3 was defined by high rates of heart failure
and rhythm disturbance and appeared to be an
almost purely cardiac symptom group, with
high rates of heart failure and dyspnea in both
ATTR duration groups (Fig. 1c). The almost
overlapping curves in Fig. 1c indicated that
ATTR duration had little effect. This class
included 22% of the patients with ATTR
duration \4 years and 28% of those
with C4 years duration (Table 1).
LC4: Moderate to Severe Neuropathy
LC4 was the largest, comprising 46% of the
patients with ATTR duration\4 years and 31%
of those with C4 years duration (Table 1). This
class was characterized by moderate to high
probabilities of neuropathic symptoms and
relatively low probabilities of the other
symptoms (Fig. 1d).
Comparisons of Health Status Measures
by LC and ATTR Duration
Table 2 compares patient characteristics and
health status measures by LC and ATTR
duration. Patients with C4 years of ATTR
disease duration were older across the four
LCs. Overall, patients in LC3 were the oldest,
reflecting the tendency for the generally later
onset of cardiac symptoms. ATTR duration was
similar (ranging from 1.5 to 2.6 years) across the
Table 1 Class membership and mean assignment probabilities by LC and ATTR disease duration
ATTR duration <4 years ATTR duration ‡4 years
LC: 1 2 3 4 1 2 3 4
Number of patients 87 86 120 256 59 114 119 130
Class membership probability 0.16 0.17 0.22 0.46 0.14 0.27 0.28 0.31
Mean assignment probabilitya 0.93 0.91 0.98 0.93 0.97 0.94 0.96 0.94
ATTR transthyretin amyloidosis, LC latent class, LC1 severe neuropathy/severe autonomic, LC2 moderate to severe
neuropathy/low to moderate autonomic involvement, LC3 severe cardiac, LC4 moderate to severe neuropathy
a The mean assignment probability is the mean within LC and ATTR duration group of the probabilities used to assign
individuals to LCs. Each individual had a probability of belonging to each of the four LCs. The largest of these four
probabilities was used for assignment to the corresponding LC
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Fig. 1 Item response probabilities by LC and disease
duration (\4 and C4 years): a LC1, b LC2, c LC3,
d LC4. LC latent class, LC1 severe neuropathy/severe
autonomic, LC2 moderate to severe neuropathy/low to
moderate autonomic involvement, LC3 severe cardiac, LC4
moderate to severe neuropathy
16 Neurol Ther (2015) 4:11–24
Fig. 1 continued
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four LCs if it was\4 years, compared with a
range of 8.4–12.6 years in those with C4 years
duration. A similar pattern was observed for
time since diagnosis.
Gender differences across the disease
duration categories varied by LC, except for
LC3, which had similar proportions (83% and
84%) of male patients. The rate of erectile
dysfunction (symptom of autonomic
dysfunction) was higher for the LC1 and LC2
groups than the other two, and was lowest in
the LC3 group (9% in both disease duration
groups; Table 2).
Mean changes in BP (from supine to
standing) showed the highest declines for
patients in LC1 across both disease duration
categories. The presence of orthostatic
hypotension for those with disease duration
\4 years was highest in LC1 (15.6%). For those
with disease duration C4 years in LC1, the
prevalence was 37.0%. The difference in
prevalence between disease durations was even
greater for LC2: 9.8% for\4 years and 33.3% for
C4 years. Differences for LC3 and LC4 were
more modest, but for both groups those with
longer duration had higher rates (Table 2).
In LC1 and LC2, mBMI was lower for
patients with disease duration C4 years, while
LC3 and LC4 showed relatively little difference
between disease duration categories (Table 2).
Karnofsky scores for patients with longer
disease duration were lower than those with
shorter disease duration for each LC (Table 2).
The proportions of patients who were
categorized (based on the Karnofsky score) as
having normal functions tended to be lower in
LC1 and LC2 patients with longer disease
duration, while the percentages of patients
who were unable to work were greater with
longer disease duration. Few differences in the
Karnofsky categories were seen between
patients with \4 and C4 years of disease
duration in the LC3 and LC4 groups.
The EQ-5D-3L Index and Health Status
scores in LC1 and LC2 were lower for patients
with disease duration C4 years, while for LC3
and LC4 the differences were more modest
(Table 3). Generally, the responses to the
EQ-5D-3L individual items for Mobility,
Performance of usual activities, and Self-care
indicated greater impairment across all LCs
with longer disease duration (Table 3). With
longer disease duration, LC1 and LC2 had more
patients reporting problems than LC3 and LC4.
Responses to the Pain/discomfort item were
similar. However, extreme pain or discomfort
was reported by similar proportions of patients
in LC1, LC3, and LC4 in both disease duration
categories, while in LC2 the proportions were
3.8% and 13.3% in the\4 and C4 years disease
duration categories, respectively. In both
disease duration groups, the highest
proportion of patients reporting no anxiety/
depression was in LC3 (approximately 70%),
while patients in LC1 had the highest
proportion reporting anxiety/depression.
Medical history data also showed that the
prevalence of depression was higher in
patients in LC1 with \4 years ATTR disease
duration (17.2%) and those with longer ATTR
disease duration (15.3%), compared with other
LC groups (B7.9%) regardless of disease
duration (Table 2).
Most of the differences in the health status
measures of interest were statistically significant
among the LC groups, as well as between the
two disease duration categories. The
interactions between LC membership and
ATTR disease duration were significant for
most of the comparisons, indicating that the
effects of disease duration varied by LC group.
However, the interactions for erectile
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dysfunction, presence of orthostatic
hypotension, depression from medical history,
and the EQ-5D-3L Self-care and Anxiety/
depression items were not significant.
Orthostatic hypotension was significantly
different across LC groups, but not by disease
duration category.
Comparison to a Priori Patient
Classification
Within LC1, 74.2% of patients with\4 years
ATTR disease duration would have been
classified into the neuropathic group based on
their phenotypic presentation, followed by
16.1% as mixed, while 9.7% would have been
in the cardiac group (Fig. 2). This pattern was
even stronger in the category with disease
duration C4 years, where 94.55% would have
been classified into the a priori neuropathy
group compared with 5.45% for the mixed
group, respectively.
Nearly all (98.8%) patients in LC2 with
disease duration\4 years would have been
classified as being neuropathic. However, with
longer disease duration, there was greater
variability: 75.5% would have been classified
into neuropathy, 12.8% mixed, and 11.8%
cardiac groups (Fig. 2a).
Patients in LC3 would have been largely
classified as having cardiomyopathy using the a
priori approach, regardless of disease duration.
However, among those with disease duration
C4 years, 8.0% would have been classified as
mixed, compared with 3.7% for patients with
disease duration\4 years (Fig. 2b).
Patients in LC4 would have been primarily
classified a priori as having neuropathy in both
disease duration categories (85.1% and 81.3%
for\4 and C4 years duration, respectively)
(Fig. 2). Patients would have been classified as
mixed in 9.5% and 9.8% and as having
cardiomyopathy in 5.4% and 8.9% for the \4
and C4 years duration groups, respectively.
Fig. 2 Comparison between the LC analysis classiﬁcation
and the a priori patient classiﬁcation: a disease duration
\4 years, b disease duration C4 years. P values for the
main effects of LC, the A-Du, and the interaction of LC
and A-Du were\0.0001, 0.3522, and 0.0438, respectively.
ATTR transthyretin amyloidosis, A-Du ATTR disease
duration group, LC latent class, LC1 severe neuropa-
thy/severe autonomic, LC2 moderate to severe neuropa-
thy/low to moderate autonomic involvement, LC3 severe
cardiac, LC4 moderate to severe neuropathy
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LC Groups by Mutation Type and Country
There were [40 mutations represented in this
analysis (Table S2 in the ESM), plus the non-
mutant wild type, representing 15 countries
(Table S3 in the ESM). The most common
mutation in the world, the V30M mutation,
was predominant in the LC groups involving
neuropathy (i.e., LC1, LC2, and LC4), regardless
of disease duration, although it was found in all
four LCs. For LC3 (Severe cardiac), the primary
mutation was V122I followed by the non-
mutant wild type. Most non-V30M mutations
occurred with low frequency (\10 patients per
mutation), making it difficult to discern a
distribution pattern, though most of these
mutations were dispersed across the LC groups.
DISCUSSION
This study is the first attempt to empirically
categorize a broad spectrum of patients with
ATTR based on signs and symptoms using LCA.
After testing various models, we found a
four-class LC solution best suited the data.
These classes were characterized by the
predominant symptoms to be severe
neuropathy/severe autonomic (LC1), moderate
to severe neuropathy/low to moderate
autonomic involvement (LC2), severe cardiac
(LC3), and moderate to severe neuropathy
(LC4). These groups reflected the variability in
the clinical presentation of ATTR. The measures
of health status varied by LC in interpretable
patterns, supporting the LCA approach.
Disease duration affected the clinical
presentation for the majority of patients with
ATTR studied, with either a greater number of
symptoms emerging as the disease progressed or
an apparent increase in the frequency of the
earlier symptoms over time. The exception was
LC3, in which clinical presentation varied little
between the disease duration groups.
This analysis included many different
mutations to arrive at patient groups that
would encompass the entire range of ATTR. In
this study, the most common mutation in the
world, the V30M mutation, was found in all
four LCs, mirroring the variability in symptom
presentation in that single mutation [5, 6].
Future LCA work could be done to further
explore this variability as well as the impact of
the age of disease onset.
This four-class LC solution offers promise in
categorizing patients with ATTR across the
spectrum of disease; it also offers a refinement
of the a priori approach classifying patients with
ATTR based on phenotype: neuropathy, cardiac,
or mixed. Although there was overlap between
these two classification approaches, a particular
strength of the LCA solution was that it allowed
for finer distinctions between patients with
neuropathy and those with mixed
presentation. An additional strength was that
it incorporated disease duration, which is an
important factor in understanding ATTR.
The LCA approach may be useful for
studying ATTR disease progression over time
and in examining the clinical outcome of this
disease. Although this study was limited in its
cross-sectional approach to disease duration,
future work could include the application of
longitudinal LCA to look at shifts between the
LCs over time to confirm and extend the results
reported here.
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